Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.53 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28106293 | 0.81 | KDR (0.44) | KDREGFRPDGFRB | |
| SCHEMBL15618299 | 0.80 | MKNK1 (0.58) | MKNK1KDREGFRSYKKIF11 | |
| SCHEMBL15618647 | 0.80 | MKNK1 (0.58) | MKNK1KDREGFRSYKKIF11 | |
| SCHEMBL15618296 | 0.80 | MKNK1 (0.58) | MKNK1KDREGFRSYKKIF11 | |
| SCHEMBL15618290 | 0.80 | MKNK1 (0.55) | MKNK1KDREGFRSYKKIF11 | |
| SCHEMBL15618212 | 0.80 | MKNK1 (0.51) | MKNK1KDREGFRSYKKIF11 | |
| SCHEMBL18167313 | 0.79 | MKNK1 (0.53) | MKNK1KDREGFRSYKKIF11 | |
| SCHEMBL15618202 | 0.77 | MKNK1 (0.50) | MKNK1MAPTPOLB | |
| SCHEMBL15618354 | 0.77 | MKNK1 (0.60) | MKNK1KDREGFR | |
| SCHEMBL15618562 | 0.76 | MKNK1 (0.64) | MKNK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897957-B1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-10-26 | — | — | EP | claimed |
| US-9382255-B2 | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-05 | — | — | US | claimed |
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | US | claimed |
| EP-2897957-B1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-9382255-B2 | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9382255-B2 | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | US | disclosed |
| EP-2897957-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014044691-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-03-27 | — | — | WO | disclosed |
| US-20100113606-A1 | AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113606-A1 | AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR | ADRB1, ADRB2, ADRB3 | MKNK1 3686/4885KDR 1390/4885EGFR 3969/4885 |
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | MKNK1, MKNK2, MAP3K20 | MKNK1 1/4885KDR 136/4885EGFR 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.